PEG-ADA is used as an enzyme replacement therapy for patients with ADA deficiency. Activity in plasma is measured as the conversion of adenosine to inosine.
Patients with adenosine deaminase (ADA) deficiency may be treated with an infusion of PEG-ADA. ADA activity in plasma, together with red cell dATP levels, are useful for monitoring efficacy of treatment.
Related condition or disease:
Enzyme replacement therapy for adenosine deaminase deficiency.
Working with our NHS service partners to set the standard for the future of pathology
Viapath is a founding member of The Association of Independent Pathology Providers (AIPP), which is a trade association representing innovative research-based diagnostic testing companies. www.pathologyassociation.com
Copyright 2014 Viapath Group LLP. Viapath, the Viapath logo and Nutris are registered trademarks of Viapath Group LLP.